1. hematologic cytopenias: absolute neutrophil count (anc) \<1500/mm3, hgb\<7.0 and/or platelets \<100,000/mm3 2. subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. 3. active malignancy, solid tumors, and current or recent chemotherapy 4. concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) 5. active hiv viremia, or any other uncontrolled secondary infection. 6. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone 7. subjects with severe sepsis with vasopressors or extrapulmonary organ failure: 8. aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance \<30 ml/min 9. pregnant women or women who are breastfeeding 10. any condition, per opinion of pi that would affect subject safety and/or compliance 11. prior hypersensitivity to decitabine

1. hematologic cytopenias: absolute neutrophil count (anc) \<1500/mm3, hgb\<7.0 and/or platelets \<100,000/mm3 2. subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. 3. active malignancy, solid tumors, and current or recent chemotherapy 4. concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) 5. active hiv viremia, or any other uncontrolled secondary infection. 6. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone 7. subjects with severe sepsis with vasopressors or extrapulmonary organ failure: 8. aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance \<30 ml/min 9. pregnant women or women who are breastfeeding 10. any condition, per opinion of pi that would affect subject safety and/or compliance 11. prior hypersensitivity to decitabine

hematologic cytopenias: absolute neutrophil count (anc) <1500/mm3, hgb<7.0 and/or platelets <100,000/mm3 subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. active malignancy, solid tumors, and current or recent chemotherapy concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) active hiv viremia, or any other uncontrolled secondary infection. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone subjects with severe sepsis with vasopressors or extrapulmonary organ failure: aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance <30 ml/min pregnant women or women who are breastfeeding any condition, per opinion of pi that would affect subject safety and/or compliance prior hypersensitivity to decitabine

hematologic cytopenias: absolute neutrophil count (anc) <1500/mm3, hgb<7.0 and/or platelets <100,000/mm3 subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. active malignancy, solid tumors, and current or recent chemotherapy concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) active hiv viremia, or any other uncontrolled secondary infection. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone subjects with severe sepsis with vasopressors or extrapulmonary organ failure: aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance <30 ml/min pregnant women or women who are breastfeeding any condition, per opinion of pi that would affect subject safety and/or compliance prior hypersensitivity to decitabine

1. hematologic cytopenias: absolute neutrophil count (anc) <1500/mm3, hgb<7.0 and/or platelets <100,000/mm3 2. subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. 3. active malignancy, solid tumors, and current or recent chemotherapy 4. concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) 5. active hiv viremia, or any other uncontrolled secondary infection. 6. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone 7. subjects with severe sepsis with vasopressors or extrapulmonary organ failure: 8. aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance <30 ml/min 9. pregnant women or women who are breastfeeding 10. any condition, per opinion of pi that would affect subject safety and/or compliance 11. prior hypersensitivity to decitabine

1. hematologic cytopenias: absolute neutrophil count (anc) <1500/mm3, hgb<7.0 and/or platelets <100,000/mm3 2. subjects receiving or enrolled in clinical trial for other investigational treatment for sars- 2-cov. 3. active malignancy, solid tumors, and current or recent chemotherapy 4. concomitant use of nonbiologic immunosuppressants (e.g. janus kinase (jak) inhibitors, bruton's tyrosine kinase (btk) inhibitors) 5. active hiv viremia, or any other uncontrolled secondary infection. 6. concurrent immunomodulating biologics or use of palifermin, dipyrone, deferiprone 7. subjects with severe sepsis with vasopressors or extrapulmonary organ failure: 8. aspartate aminotransferase (ast) / alanine aminotransferase (alt) /alkaline phosphatase (alk) phos ≥3x upper limit of normal (uln) and total bilirubin (tbili) ≥2x uln; or creatinine clearance <30 ml/min 9. pregnant women or women who are breastfeeding 10. any condition, per opinion of pi that would affect subject safety and/or compliance 11. prior hypersensitivity to decitabine